Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | LPL | P06858 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802448 | 1.00 | CA2 (0.38) | CA2LPLLIPGENPP2CA1 | |
| Water SCHEMBL1961682 | 0.98 | CA2 (0.37) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL22211511 | 0.86 | — | — | |
| SCHEMBL31276726 | 0.79 | LPL (0.41) | CA2LPLLIPGCA1CXCR1 | |
| SCHEMBL850656 | 0.79 | LPL (0.41) | CA2LPLLIPGCA1CXCR1 | |
| SCHEMBL29956576 | 0.79 | NPC1 (0.38) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL29161282 | 0.75 | MGLL (0.39) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL1269058 | 0.74 | CXCR2 (0.36) | CA2LPLLIPGCA1TSHR | |
| SCHEMBL29955625 | 0.74 | CA2 (0.48) | CA2LPLLIPG | |
| SCHEMBL19144049 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BOARD INSTITUTE, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4027993-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| WO-2021050700-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| CN-107108478-B | URAT1 inhibitors | 日本化学药品株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| US-6765096-B1 | ANTIALLERGIC AGENT, IMMUNOSUPPRESSANT | SHIONOGI & CO., LTD. (JP) | 2004-07-20 | — | — | US | disclosed |
| EP-1219606-A1 | TRICYCLIC COMPOUNDS BEARING ACYLOXYMETHOXYCARBONYL PENDANTS | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | CA2 1511/4885LPL 2043/4885LIPG 2424/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | CA2 511/4885LPL 3016/4885LIPG 4235/4885 |
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | PTGES2, PTGS2, PTGES | CA2 654/4885LPL 407/4885LIPG 175/4885 |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | TNF, TNFRSF1A, CD40 | CA2 4310/4885LPL 4619/4885LIPG 4254/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | CA2 4310/4885LPL 4619/4885LIPG 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.